



TSX: RVX

Resverlogix Corp. Annual General Meeting

October 31, 2019



Forward Looking Statement

This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this presentation may include forward looking information relating to the Phase 3 BETonMACE clinical trial, vascular cognitive dementia, chronic kidney disease, fabry disease and pulmonary arterial hypertension clinical trials, and the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Donald McCaffrey


Email: don@resverlogix.com

Phone: 403-254-9252


Website: www.resverlogix.com

- There is still a **high unmet need** in high-risk CVD/diabetes patients with ACS, renal disease and cognitive impairment for novel outcomes based treatment approaches
- Apabetalone is a first and only-in-class **Phase 3** select BET inhibitor with a highly differentiated mechanism of action targeting the reduction of MACE in high-risk CVD/diabetes patients
- **November 16, 2019** – BETonMACE results to be presented during a **Late Breaking Science** session during the American Heart Association (AHA) conference
 - **Academic embargo restrictions will be strictly adhered to until November 16th**
 - **Monday, November 18, 2019** – Resverlogix to hold a pre-market open conference call on additional key BETonMACE endpoints; details to be announced soon via news release
 - **Early December** – Cognitive impairment data will continue to be embargoed until Clinical Trials on Alzheimer's Disease conference (CTAD: Dec. 4 – 7, 2019) when we expect to present additional BETonMACE results
- BETonMACE safety confirmed in **9 DSMB reports**, additional data available November 16th.
- Robust intellectual property position for **composition, use, and manufacturing**, with patent life ranging from **2027 to 2034**


Apabetalone Mechanism of Action




Apabetalone Mechanism of Action



BETonMACE Trial Timeline



BETonMACE Study Design



BETonMACE a Global, Multi-centered Clinical Trial



With 14 approved countries around the world,
BETonMACE included patients randomized at 220 different sites

Primary Objective

- To evaluate if treatment with apabetalone as compared to placebo increases time to the first occurrence of triple MACE. Triple MACE is defined as a single composite endpoint of CV death or non fatal MI or stroke.

Key Inclusion Criteria

- Type 2 Diabetes Mellitus
 - HbA1c >6.5% or history of diabetes medications
- Acute coronary syndrome 7-90 days prior to the screening visit
 - Unstable angina (Limited to 25% of total participants) or acute myocardial infarction
- Low HDL cholesterol
 - <40 mg/dL (1.04 mmol/L) for males; <45 mg/dL (1.17 mmol/L) for females at the screening visit

Primary Endpoint

- Time to first occurrence of adjudication-confirmed triple MACE

Key Secondary and Exploratory Endpoints

- Change in kidney function in chronic kidney disease sub-population
 - Baseline estimated glomerular filtration rate (eGFR) <60 mL/min/1.7m²
- Change in Montreal Cognitive Assessment (MoCA)
 - Evaluated in at-risk sub-population (>70 years old at randomization)

How Will BETonMACE Data be Presented at AHA?

1st Step – A Statistical Analysis Called a Forest Plot

Primary End Point

First occurrence of primary end point – Announced September 30th, 2019 – Marginal miss

Key Secondary End Points

First occurrence of primary end point or hospitalization for unstable angina or urgent or emergency revascularization procedure

First and recurrent primary end point events

Cardiovascular death or non-fatal myocardial infarction

Coronary heart disease death or non-fatal myocardial infarction

Non-fatal myocardial infarction

Cardiovascular death

Stroke

All cause mortality

First hospitalization for congestive heart failure

Other Pre-specified End Points

First and recurrent hospitalization for CHF

First occurrence of primary end point, excluding undetermined death

Hazard Ratio (95% CI)

0.25

0.50

1.00

2.00

Apabetalone Better

Placebo Better


Hazard ratios are indicative of the effect size, while 95% confidence intervals (CI) are a measure of our level of certainty in the result

Remember, Placebo in this trial includes the top standard of care available in the world


Data on this side of the line would indicate that Apabetalone outperformed placebo. HR less than 1.0

Data on this side of the line would indicate that Placebo outperformed drug. HR greater than 1.0

A Bad Forest Plot would Look Something Like This



A Very Good Forest Plot would Look Something Like This




Questions for, and considerations around, various paths forward:

| | | |
|---|--|--------------------------------------|
| 1 | Can Resverlogix proceed with the current registration of Apabetalone for use in indications that clearly demonstrated success in BETonMACE trial? | Longshot but possible |
| 2 | Continuation of the BETonMACE trial in a bolt-on fashion? Adding enough new patients to achieve the power calculations. This scenario can be partnered etc. if required. | Good Potential |
| 3 | Commencement in new trials for varying indications such as the existing CVD in Diabetics, orphan indications, Renal, Cognitive impairment etc.? | Expensive but partners are available |

Overcoming Phase 3 Obstacles

| Drug Name | Year | Indication | Company | Initial Result | Regulatory Decision |
|------------------|------|------------------------------------|--------------------------|---|--|
| Situro | 2019 | Drug-Resistant Tuberculosis | Johnson & Johnson | Demonstrated improved ability to kill tuberculosis bacteria in Phase 3 trial, however 10 patients died in treatment group, compared with 2 in placebo | Approved |
| Vyndaqel | 2019 | Transthyretin-Mediated Amyloidosis | Pfizer | FDA initially rejected the drug in 2012 as a therapy for familial amyloid polyneuropathy, while dozens of other countries approved it for that indication | Approved |
| Aducanumab | 2019 | Alzheimer's Disease | Biogen | Biogen halted two Phase 3 trials (EMERGE and ENGAGE) after futility analyses showed they were unlikely to yield significant results, but later requested FDA approval based on subset analysis of the pooled data | Decision pending |
| Zyprexa Pamaoate | 2014 | Schizophrenia | Eli Lilly | Phase 3 trial denoted heavy sedation in a small number of patients at least one hour post-injection, but clear efficacy | Approved, with warning label |
| Solanezumab | 2012 | Alzheimer's Disease | Eli Lilly | Pooled results from two failed Phase 3 trials indicated improved cognition and reduced amyloid burden | TBD, trial ongoing |
| Nuplazid | 2009 | Parkinson's Related-Psychosis | Acadia Pharmaceuticals | After not meeting pre-specified end point in Phase 3 trial, Acadia argued to FDA to revise the scale used to assess efficacy | Approved, after additional small trial |
| Fotolyn | 2009 | Rare Blood Cancers | Spectrum Pharmaceuticals | Reduced tumors in 29/107 patients, with no measured improvement in life expectancy, and poor safety/tolerability; positive surrogate measurements presented to FDA | Accelerated approval |
| Ulroic | 2009 | Gout | Takeda Pharmaceuticals | Rejected due to adverse CV events in 2005/6 Phase 3, but a follow-up trial saw normative safety and tolerability; Post-market surveillance confirmed elevated CV risk | Approved |

RESVERLOGIX – Short Term Timelines





The image displays two complex molecular structures rendered as wireframes. The structure on the left, associated with BETonMACE, is a large, multi-lobed molecule with a dense network of blue lines. The structure on the right, associated with Apabetalone, features a prominent central hexagonal ring system with several fused and branched rings, rendered in black lines. The background is a light blue gradient with faint, out-of-focus silhouettes of people in a laboratory setting.

BETonMACE & Apabetalone